Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach

ConclusionPatients with eGFR < 30 ml/min incurred 10‐year costs 15‐fold higher than those with normal eGFR. By estimating the expected duration in each renal state and incorporating associated annual costs, disease severity at presentation can be used to anticipate future healthcare costs. This is critical knowledge for cost‐effectiveness evaluations of novel therapies.This article is protected by copyright. All rights reserved.

Source: Arthritis Care and Research - November 28, 2017 Category: Rheumatology Authors: Megan R.W. Barber, John G. Hanly, Li Su, Murray B. Urowitz, Yvan St Pierre, Juanita Romero ‐Diaz, Caroline Gordon, Sang‐Cheol Bae, Sasha Bernatsky, Daniel J Wallace, David A. Isenberg, Anisur Rahman, Ellen M. Ginzler, Michelle Petri, Ian N. Bruce, Pau Tags: Original Article Source Type: research